Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study
Raghunandan, C., Agrawal, S., Dubey, P., Choudhury, M
3B, Fig
Retatrutide at 12 mg weekly currently produces the largest weight loss of any published Phase 3 GLP-1-class compound, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints
Compounded GLP-1 agents are not FDA-approved but are synthesized under USP standards by licensed compounding pharmacies
Commonly discussed side effects in this medication class may include nausea, vomiting, constipation, diarrhea, reflux, abdominal discomfort, reduced appetite, fatigue, dehydration risk, and food aversions